| Placebo (n = 515) | Ertugliflozin 5 mg (n = 519) | Ertugliflozin 15 mg (n = 510) |
---|---|---|---|
Any AE | 263 (51.1) | 236 (45.5) | 257 (50.4) |
Serious AE | 15 (2.9) | 17 (3.3) | 12 (2.4) |
Discontinuation due to AEa | 9 (1.7) | 12 (2.3) | 7 (1.4) |
Hypovolemia | 9 (1.7) | 4 (0.8) | 5 (1.0) |
Osmotic diuresis | 5 (1.0) | 15 (2.9) | 12 (2.4) |
Orthostatic change in SBP | |||
 Baseline, n/m (%) | 14/502 (2.8) | 21/516 (4.1) | 16/494 (3.2) |
 Week 6, n/m (%) | 16/477 (3.4) | 16/493 (3.2) | 17/476 (3.6) |
 Week 26, n/m (%) | 18/446 (4.0) | 16/475 (3.4) | 17/458 (3.7) |
Orthostatic change in DBP | |||
 Baseline, n/m (%) | 72/502 (14.3) | 80/516 (15.5) | 81/494 (16.4) |
 Week 6, n/m (%) | 74/477 (15.5) | 81/493 (16.4) | 68/476 (14.3) |
 Week 26, n/m (%) | 65/446 (14.6) | 82/475 (17.3) | 75/458 (16.4) |